1. Introduction {#sec1}
===============

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used drugs for treatment of rheumatoid and osteoarthritis as they relief pain and inflammation ([@bib12]). It has been reported that NSAIDs inhibit the activity of cyclooxygenase-1 and cyclooxygenase-2 enzymes and thereby suppress the formation of thromboxane and prostaglandin ([@bib9]; [@bib10]). Chronic intake of NSAIDs leads to undesirable side effects such as gastrointestinal injury, renal and cardiovascular damages ([@bib11]; [@bib19]; [@bib6]).

Diclofenac is a widely used NSAID that is usually prescribed for its analgesic, anti-inflammatory, and anti-pyretic activities ([@bib21]). Diclofenac causes hepatotoxicity. The mechanism of Diclofenac-induced liver toxicity in humans is idiosyncratic. Diclofenac is metabolized in hepatocyte by multiple cytochrome P-450 enzymes resulting in formation of drug-protein adducts, glutathione (GSH) conjugation, and mitochondrial dysfunction and organ damage ([@bib24]). However, it has been documented that diclofenac rather than its metabolite is responsible for its toxicity ([@bib39]). The kidney is also affected by diclofenac as it contributes to nephritis and nephrotoxicity ([@bib47]). Moreover, diclofenac administration results in gastrointestinal tract problems such as gastric mucosa bleeding, deficiency in gastric blood flow and apoptosis ([@bib27]).

Natural products are used as therapeutic agents for the treatment of various diseases due to their minimal side effects ([@bib35]). Royal jelly (RJ) is a natural honeybee product produced from the hypopharyngeal gland of young worker honey bees (*Apis mellifera Linne*). RJ is a mixture of free amino acids, proteins, sugars, lipids, vitamins, and minerals ([@bib4]). RJ exhibits anti-oxidant ([@bib1]), anti-inflammatory ([@bib30]), immunomodulatory ([@bib18]), anti-tumor ([@bib56]), anti-hypercholesterolemic ([@bib25]), anti-microbial ([@bib15]) and anti-allergic ([@bib46]) activities. Moreover, RJ has shown neuroprotective effects in stress-induced animal models ([@bib54]), aging ([@bib48]), and drug-induced neurotoxicity ([@bib40]).

Although it has been reported that RJ exhibited protective effect against carbon tetrachloride-induced hepatotoxicity ([@bib14]) and cisplatin-induced nephrotoxicity ([@bib51]), its effect on diclofenac induced hepato-renal damage and gastrointestinal ulcerations in rats has not been yet investigated.

Therefore this study aims to evaluate the possible ameliorating effect of RJ on biochemical, histopathological, and immunohistochemical changes in diclofenac induced hepato-renal damage and gastrointestinal ulcerations in rats.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

Forty adult male Wistar rats weighing 180--200 g were used in the current study. Standard food pellets and tap water were supplied ad libitum. Animals and food pellets were obtained from the animal house colony of the National Research Center (NRC, Egypt). The study was conducted in accordance with the National Research Centre--Medical Research Ethics Committee (NRC-MREC) for the use of animal subjects and following the recommendations of the National Institutes of Health Guide for Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978).

2.2. Drugs and chemicals {#sec2.2}
------------------------

Diclofenac sodium (Voltarene®, 50 mg coated tablets; Novartis Egypt) and Royal Jelly (Royal Jelly®^,^ 1000 mg soft gelatin capsules; Pharco pharmaceuticals, Egypt) were used throughout the study. All other chemicals were of highest analytical grade available.

2.3. Experimental design and treatment protocol {#sec2.3}
-----------------------------------------------

Animals were randomly allocated into four groups (10 rats each). Rats of the 1st group received only saline intraperitoneally and served as normal control group. Group 2 received diclofenac (50 mg/kg/day, I.P.) for 7 days and served as diclofenac-control group. Groups 3 and 4 received diclofenac (50 mg/kg/day, I.P.) for 7 days and royal jelly (RJ; 150 and 300 mg/kg/day, P.O.) respectively for 30 days. All animals were sacrificed 24 h after the last treatment after overnight fasting.

3. Methods {#sec3}
==========

3.1. Serum biochemical analysis {#sec3.1}
-------------------------------

Twenty-four hours after the last drug dose, rats were anaesthetized with diethyl ether and blood samples were withdrawn from the retro-orbital venous plexus. Collected blood samples were allowed to stand for 10 min at room temperature then centrifuged at 4 °C using cooling centrifuge (Laborezentrifugen, 2k15, Sigma, Germany) at 3000 r.p.m for 10 min and sera were separated for the assessment of levels of urea, creatinine as well as aspartate aminotransferase (AST), alanine aminotransferase (ALT) using commercially available kits (Biodiagnostic, Egypt).

3.2. Tissue biochemical analysis {#sec3.2}
--------------------------------

Immediately after blood sampling, animals were sacrificed by cervical dislocation under ether anesthesia. The two kidneys, the livers, stomachs and intestines were harvested from each rat. All organs were immediately dissected out, and rinsed with PBS to remove excess blood. Stomachs and intestines were examined for ulcer counts and severity. Parts from kidneys, livers, stomachs & intestines were homogenized (MPW-120 homogenizer, Med instruments, Poland) to obtain 20% homogenate that was stored overnight at --20 °C. The homogenates were centrifuged for 5 min at 5000 x g using a cooling centrifuge (Sigma and laborzentrifugen, 2k15, Germany).

Tissue contents of prostaglandin-E2 (PGE2) and myeloperoxidase (MPO) were assessed in hepatic, renal, gastric and intestinal tissues using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer\'s instructions.

3.3. Gastric and intestinal ulcer count and score {#sec3.3}
-------------------------------------------------

Stomachs and intestines were tested for ulcer counts. The stomachs were opened along the greater curvature; the mucosa of each rat was examined for macroscopic mucosal lesions. Gastric mucosal lesions were evaluated by visual scores and results expressed as the number of lesions/rat ([@bib43]).

The small intestine was also removed and opened on the side opposite the mesentery and the lesions were assessed as described above for gastric ulcers ([@bib8]).

3.4. Histopathological examination {#sec3.4}
----------------------------------

Other parts of the kidneys, livers, stomachs and intestines were fixed in 10% neutral buffered formalin and embedded in paraffin wax. 4μm thick sections were stained with Hematoxylin and Eosin (H&E) and examined using binocular Olympus CX31 microscope ([@bib7]).

3.5. Immunohistochemical determination of cyclooxygenase-2 (COX-2) {#sec3.5}
------------------------------------------------------------------

Immunohistochemical staining of anti-cyclooxygenase-2 antibodies was performed on polylysine-coated slides of the selected organs. The organs were fixed in neutral buffered formalin and then embedded in paraffin. Following deparaffinization, sections were exposed to 3% hydrogen peroxide for 10 min, followed by rinsing three times in Tris buffer (pH 7.4) for 10 min. Sections were incubated under humid conditions using an anti-COX-2 antibody (1:100). The specimens were counterstained with Hematoxylin & Eosin. Negative controls were prepared by substituting normal mouse serum for each primary antibody ([@bib38]).

3.6. Immunohistochemical determination of inducible nitric oxide synthase (iNOS) {#sec3.6}
--------------------------------------------------------------------------------

Immunohistochemical staining of anti- inducible nitric oxide synthase antibodies was performed by streptoavidin--biotin. Four- micrometer--thick sections were deparaffinized and incubated with fresh 0.3% hydrogen peroxide in methanol for 30 min at room temperature. The specimens were then incubated with anti- iNOS antibody as the primer antibody at a 1:100 dilution. The specimens were counterstained with Hematoxylin & Eosin. Negative controls were prepared by substituting normal mouse serum for each primary antibody.

3.7. Statistical analysis {#sec3.7}
-------------------------

All the values are presented as means ± standard error of the means (SEM). Comparisons between different groups were carried out using one way analysis of variance (ANOVA) followed by *Tukey\'s* multiple comparison post hoc test. Difference was considered significant when *p ˂0.05*. GraphPad prism® software (version 6 for Windows, San Diego, California, USA) were used to carry out these statistical tests.

4. Results {#sec4}
==========

4.1. Effects of royal jelly on serum hepatic (aspartate transaminase; AST & alanine transaminase; ALT) and renal (creatinine & urea) functions in diclofenac-induced hepato-renal damage in rats {#sec4.1}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Diclofenac (50 mg/kg, I.P.) resulted in hepatic damage in rats as evidenced by the significant elevation of ALT and AST to 220% and 119% respectively as compared to the normal control group. Royal jelly (150 & 300 mg/kg/day, P.O.) significantly decreased the elevated serum ALT to 61% and 42% and decreased the elevated serum AST to 97% and 49% respectively as compared to the diclofenac-control group.

Diclofenac also resulted in renal damage in rats as evidenced by the significant elevation of serum creatinine and urea to 272% and 217% respectively as compared to the normal control group. Royal jelly (150 & 300 mg/kg/day, P.O.) significantly decreased the elevated serum creatinine to 65% and 48% and decreased the elevated serum urea to 80% and 56% respectively as compared to the diclofenac-control group ([Table 1](#tbl1){ref-type="table"}).Table 1Effects of royal jelly on serum hepatic (aspartate transaminase; AST & alanine transaminase; ALT) and renal (creatinine & urea) functions in diclofenac-induced hepato-renal damage in rats.Table 1GroupsHepatic function testRenal function testALT (U/L)AST (U/L)Creatinine (mg/dl)Urea (mg/dl)Normal control45.56 ± 2.5840.23 ± 3.562.81 ± 0.2447.21 ± 3.95Diclofenac-control (50 mg/kg, I.P.)105.83^a^ ± 5.6996.01^a^ ± 4.227.65^a^ ± 0.82102.35^a^ ± 2.87Diclofenac + RJ (150 mg/kg, P.O.)86.41^a,b^ ± 3.4978.63^a,b^ ± 4.085.00^a,b^ ± 0.5181.54^a,b^ ±7.39Diclofenac + RJ (300 mg/kg, P.O.)68.35^a,b^ ± 2.4160.40^a,b^ ± 2.073.71^a,b^ ± 0.3157.80^b^ ± 3.39[^1][^2][^3][^4]

4.2. Effects of royal jelly on gastric and intestinal ulcer count in diclofenac-induced gastrointestinal ulcerations in rats {#sec4.2}
----------------------------------------------------------------------------------------------------------------------------

Diclofenac (50 mg/kg, I.P.) resulted in severe gastric and intestinal ulceration in rats as evidenced by the visual inspection of ulcer count in both gastric and intestinal tissues. Gastric and intestinal ulcers were elevated to 317% and 260% respectively as compared to the normal control group. Royal jelly (150 mg/kg/day, P.O.) significantly decreased the number of gastric ulcers to 25% as compared to the diclofenac-control group. Royal jelly (150 & 300 mg/kg/day, P.O.) totally inhibited the gastric and intestinal ulcerations and normalized both gastric and intestinal mucosal tissues as compared to the diclofenac-control group ([Table 2](#tbl2){ref-type="table"}).Table 2Effects of royal jelly on gastric and intestinal ulcer count in diclofenac-induced gastrointestinal ulcerations in rats.Table 2GroupsGastric Ulcer countIntestinal Ulcer countNormal control0.0 ± 0.00.0 ± 0.0Diclofenac-control (50 mg/kg, I.P.)3.17^**a**^ ± 0.62.60^**a**^ ± 0.62Diclofenac + RJ (150 mg/kg, P.O.)0.80^**a,b**^ ± 0.340.0^**b**^ ± 0.0Diclofenac + RJ (300 mg/kg, P.O.)0.0^**b**^ ± 0.00.0^**b**^ ± 0.0[^5][^6][^7][^8]

4.3. Effects of royal jelly on hepatic, renal, gastric and intestinal tissue concentration of prostaglandin E2 (PGE2) in diclofenac-induced hepato-renal damage and gastrointestinal ulcerations in rats {#sec4.3}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Diclofenac (50 mg/kg, I.P.) resulted in hepato-renal damage and gastrointestinal ulcerations in rats as evidenced by the significant reduction of hepatic, renal, gastric and intestinal tissue concentrations of PGE2 to 77%, 82%, 72% and 85% respectively as compared to the normal control group. Royal jelly (150 mg/kg/day, P.O.) significantly elevated the reduced hepatic, renal, gastric and intestinal tissue concentrations of PGE2 to 86%, 89%, 94% and 87% respectively as compared to the diclofenac-control group.

Royal jelly (300 mg/kg/day, P.O.) significantly elevated the reduced hepatic, renal, gastric and intestinal tissue concentrations of PGE2 to 88%, 91%, 95% and 90% respectively as compared to the diclofenac-control group ([Table 3](#tbl3){ref-type="table"}).Table 3Effects of royal jelly on hepatic, renal, gastric and intestinal tissue concentrations of prostaglandin E2 (PGE2) in diclofenac-induced hepato-renal damage and gastrointestinal ulcerations in rats.Table 3GroupsPGE2 (ng/g tissue)HepaticRenalGastricIntestinalNormal control10.59 ± 0.3311.27 ± 0.059.62 ± 0.0510.78 ± 0.06Diclofenac-control (50 mg/kg, I.P.)8.17^a^ ± 0.029.23^a^ ± 0.056.95^a^ ± 0.128.05^a^ ± 0.08Diclofenac + RJ (150 mg/kg, P.O.)9.06^a,b^ ± 0.029.96^a,b^ ± 0.629.00^a,b^ ± 0.019.37^a,b^ ± 0.04Diclofenac + RJ (300 mg/kg, P.O.)9.32^a,b^ ± 0.1810.20^a,b^ ± 0.019.13^a,b^ ± 0.109.73^a,b^ ± 0.05[^9][^10][^11][^12]

4.4. Effects of royal jelly on hepatic, renal, gastric and intestinal tissue concentrations of myeloperoxidase (MPO) in diclofenac-induced hepato-renal damage and gastrointestinal ulcerations in rats {#sec4.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Diclofenac (50 mg/kg, I.P.) resulted in hepato-renal damage and gastrointestinal ulcerations in rats as evidenced by the significant elevation of hepatic, renal, gastric and intestinal tissue concentrations of MPO to 258%, 160%, 202% and 160% respectively as compared to the normal control group. Royal jelly (150 mg/kg/day, P.O.) significantly decreased the elevated hepatic, renal, gastric and intestinal tissue concentrations of MPO to 55%, 81%, 73% and 80% respectively as compared to the diclofenac-control group.

Royal jelly (300 mg/kg/day, P.O.) significantly decreased the elevated hepatic, renal, gastric and intestinal tissue concentrations of MPO to 43%, 64%, 53% and 73% respectively as compared to the diclofenac-control group ([Table 4](#tbl4){ref-type="table"}).Table 4Effects of royal jelly on hepatic, renal, gastric and intestinal tissue concentration of myeloperoxidase (MPO) in diclofenac-induced hepato-renal damage and gastrointestinal ulcerations in rats.Table 4GroupsMPO (ng/g tissue)HepaticRenalGastricIntestinalNormal control14.42 ± 0.7317.63 ± 0.5512.39 ± 0.6411.40 ± 0.17Diclofenac-control (50 mg/kg, I.P.)37.25^a^ ± 2.1028.20^a^ ± 0.9124.99^a^ ± 2.0118.25^a^ ± 0.19Diclofenac + RJ (150 mg/kg, P.O.)20.62^a,b^ ± 1.0922.83^a,b^ ± 1.3918.28^a,b^ ±0.9714.59^a,b^ ±0.10Diclofenac + RJ (300 mg/kg, P.O.)16.08^b^ ± 0.9518.15^b^ ± 0.1713.23^b^ ± 0.2713.31^a,b^ ±0.23[^13][^14][^15][^16]

4.5. Histopathological examination of hepatic, renal, gastric and intestinal tissues {#sec4.5}
------------------------------------------------------------------------------------

Hepatic section ([Figure 1](#fig1){ref-type="fig"} A1), renal section ([Figure 1](#fig1){ref-type="fig"} B1), gastric section ([Figure 1](#fig1){ref-type="fig"} C1) and intestinal section ([Figure 1](#fig1){ref-type="fig"} D1) from a normal control rat shows normal histopathological picture.Figure 1Histopathological examination of hepatic, renal, gastric and intestinal tissues. Photomicrograph of a hepatic (A1), and renal (B1), gastric (C1) and intestinal (D1) sections of a rat from a normal control group (H&E X 100). Photomicrograph of a hepatic (A2), and renal (B2), gastric (C2) and intestinal (D2) sections prepared from a diclofenac-control rat (H&E X 100). Photomicrograph of a hepatic (A3), and renal (B3), gastric (C3) and intestinal (D3) sections prepared from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment (H&E X 100). Photomicrograph of a hepatic (A4), and renal (B4), gastric (C4) and intestinal (D4) sections prepared from a rat treated with royal jelly (300 mg/kg/day, P.O.) for 30 days along with diclofenac treatment (H&E X 100).Figure 1

Hepatic section from a diclofenac-control rat shows massive histopathological distortions with fatty changes and cytoplasmic vacuolation detected in the hepatocytes at the most of the peripheral zone of the hepatic lobules ([Figure 1](#fig1){ref-type="fig"} A2).

Renal section from a diclofenac-control rat shows massive areas of fibrosis and ongoing cell apoptosis. Glomerular affection in the form of thickening of glomerular membrane whereas tubules are not much affected ([Figure 1](#fig1){ref-type="fig"} B2).

Gastric section from a diclofenac-control rat shows abnormal histological structure of the mucosa. The nuclei of the glandular lining epithelium showed nuclear pyknosis. Sloughing of superficial mucosa secreting cells is apparent with necrosis of the functioning cells of gastric glands along with inflammatory cellular infiltrate in the submucosa ([Figure 1](#fig1){ref-type="fig"} C2).

Intestinal section from a diclofenac-control rat shows distorted histological structure of the villi with lining mucosal epithelium and serosa ([Figure 1](#fig1){ref-type="fig"} D2).

Hepatic section from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows moderate improvement of the overall histopathological picture. Few inflammatory cells of infiltration were observed in the portal area ([Figure 1](#fig1){ref-type="fig"} A3).

Renal section from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows moderate improvement of the overall histopathological picture. Few fat globules are distributed all over the section ([Figure 1](#fig1){ref-type="fig"} B3).

Gastric section from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows moderate improvement of the overall histopathological picture. Widening of gastric pits can be observed due to slight atrophy of the mucous secreting cells and preserved peptic and partial cells ([Figure 1](#fig1){ref-type="fig"} C3).

Intestinal section from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows huge improvement of the overall histopathological picture ([Figure 1](#fig1){ref-type="fig"} D3).

Hepatic section ([Figure 1](#fig1){ref-type="fig"} A4), renal section ([Figure 1](#fig1){ref-type="fig"} B4), gastric section ([Figure 1](#fig1){ref-type="fig"} C4) and intestinal section ([Figure 1](#fig1){ref-type="fig"} D4) from a rat treated with royal jelly (300 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows huge improvement of the overall histopathological picture. No histopathological alterations could be seen.

4.6. Immunohistochemical determination of cyclooxygenase-2 (COX-2) in hepatic, renal, gastric and intestinal tissues {#sec4.6}
--------------------------------------------------------------------------------------------------------------------

Hepatic section ([Figure 2](#fig2){ref-type="fig"} A1), renal section ([Figure 2](#fig2){ref-type="fig"} B1), gastric section ([Figure 2](#fig2){ref-type="fig"} C1) and intestinal section ([Figure 2](#fig2){ref-type="fig"} D1) from a normal control rat shows mild positivity for COX-2 immunostaining.Figure 2Immunohistochemical determination of cyclooxygenase-2 (COX-2) in hepatic, renal, gastric and intestinal tissues. Photomicrograph of a hepatic (A1), and renal (B1), gastric (C1) and intestinal (D1) sections of a rat from a normal control group. Photomicrograph of a hepatic (A2), and renal (B2), gastric (C2) and intestinal (D2) sections prepared from a diclofenac-control rat. Photomicrograph of a hepatic (A3), and renal (B3), gastric (C3) and intestinal (D3) sections prepared from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment. Photomicrograph of a hepatic (A4), and renal (B4), gastric (C4) and intestinal (D4) sections prepared from a rat treated with royal jelly (300 mg/kg/day, P.O.) for 30 days along with diclofenac treatment (COX-2 immunohistochemistry, H&E X 100).Figure 2

Hepatic section ([Figure 2](#fig2){ref-type="fig"} A2), renal section ([Figure 2](#fig2){ref-type="fig"} B2), gastric section ([Figure 2](#fig2){ref-type="fig"} C2) and intestinal section ([Figure 2](#fig2){ref-type="fig"} D2) from a diclofenac-control rat shows negative COX-2 immunostaining.

Hepatic section ([Figure 2](#fig2){ref-type="fig"} A3), renal section ([Figure 2](#fig2){ref-type="fig"} B3), gastric section ([Figure 2](#fig2){ref-type="fig"} C3) and intestinal section ([Figure 2](#fig2){ref-type="fig"} D3) from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows moderate COX-2 immunostaining.

Hepatic section ([Figure 2](#fig2){ref-type="fig"} A4), renal section ([Figure 2](#fig2){ref-type="fig"} B4), gastric section ([Figure 2](#fig2){ref-type="fig"} C4) and intestinal section ([Figure 2](#fig2){ref-type="fig"} D4) from a rat treated with royal jelly (300 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows normalization and positivity for COX-2 immunostaining.

4.7. Immunohistochemical determination of inducible nitric oxide synthase (iNOS) in hepatic, renal, gastric and intestinal tissues {#sec4.7}
----------------------------------------------------------------------------------------------------------------------------------

Hepatic section ([Figure 3](#fig3){ref-type="fig"} A1), renal section ([Figure 3](#fig3){ref-type="fig"} B1), gastric section ([Figure 3](#fig3){ref-type="fig"} C1) and intestinal section ([Figure 3](#fig3){ref-type="fig"} D1) from a normal control rat shows no positivity for iNOS immunostaining.Figure 3Immunohistochemical determination of inducible nitric oxide synthase (iNOS) in hepatic, renal, gastric and intestinal tissues. Photomicrograph of a hepatic (A1), and renal (B1), gastric (C1) and intestinal (D1) sections of a rat from a normal control group. Photomicrograph of a hepatic (A2), and renal (B2), gastric (C2) and intestinal (D2) sections prepared from a diclofenac-control rat. Photomicrograph of a hepatic (A3), and renal (B3), gastric (C3) and intestinal (D3) sections prepared from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment. Photomicrograph of a hepatic (A4), and renal (B4), gastric (C4) and intestinal (D4) sections prepared from a rat treated with royal jelly (300 mg/kg/day, P.O.) for 30 days along with diclofenac treatment (iNOS immunohistochemistry, H&E X 100).Figure 3

Hepatic section ([Figure 3](#fig3){ref-type="fig"} A2), renal section ([Figure 3](#fig3){ref-type="fig"} B2), and intestinal section ([Figure 3](#fig3){ref-type="fig"} D2) from a diclofenac-control rat shows scattered positive iNOS immunostaining. While, gastric section ([Figure 3](#fig3){ref-type="fig"} C2) from a diclofenac-control rat shows severe significant positive iNOS immunostaining.

Hepatic section ([Figure 3](#fig3){ref-type="fig"} A3), renal section ([Figure 3](#fig3){ref-type="fig"} B3), and intestinal section ([Figure 3](#fig3){ref-type="fig"} D3) from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows minimal iNOS immunostaining. While, iNOS immunostaining for gastric section ([Figure 3](#fig3){ref-type="fig"} C3) from a rat treated with royal jelly (150 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows persistent scattered positivity.

Hepatic section ([Figure 3](#fig3){ref-type="fig"} A4), renal section ([Figure 3](#fig3){ref-type="fig"} B4), and intestinal section ([Figure 3](#fig3){ref-type="fig"} D4) from a rat treated with royal jelly (300 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows negative iNOS immunostaining. While, gastric section ([Figure 3](#fig3){ref-type="fig"} C4) from a rat treated with royal jelly (300 mg/kg/day, P.O.) for 30 days along with diclofenac treatment shows very minimal iNOS immunostaining.

5. Discussion {#sec5}
=============

The current study adds new information regarding the potential protective effect of royal jelly (RJ; 150, 300 mg/kg) against diclofenac-induced damage in rats. This study is the first to assess the role of COX-2, prostaglandin and inflammation in the protective effects of RJ against diclofenac-induced hepato-renal damage and gastrointestinal ulcerations in rats.

Diclofenac is commonly prescribed for its analgesic, anti-inflammatory, and anti-pyretic activities ([@bib21]). Despite the overspread use of diclofenac, hepato-renal and gastrointestinal injuries have been reported post its administration ([@bib27]; [@bib24]; [@bib47]).

Elevation of hepatic function enzymes reflects severe hepatocellular injury with subsequent leakage of these cytoplasmic enzymes into the circulation ([@bib41]). In this study, diclofenac administration (50 mg/kg/day, I.P.) for 7 days resulted in significant elevation of hepatic liver enzymes namely; ALT and AST. This finding indicates that diclofenac administration resulted in severe damage of the hepatic membrane. This result is in harmony with prior studies ([@bib23]; [@bib2]).

It is well established that diclofenac has a selective inhibitory effect on COX-2 than COX-1 ([@bib20]). Prostaglandins derived from COX-2 has protective effect against injury-induced by hepatotoxins such as lipopolysaccharide, acetaminophen, and carbon tetrachloride ([@bib49]). In line with this notion, diclofenac-injected rats in this study significantly exhibited reduced COX-2 protein expression and hepatic PGE2 content. In agreement with the prior study of Gan; diclofenac-induced hepatotoxicity may have resulted from reduction of PGE-2 content which originally resulted from reduction of COX-2 protein expression ([@bib21]).

MPO is a vital marker of neutrophil function and when neutrophils are activated in response to inflammation, MPO is released from cells into extra-cellular space ([@bib13]; [@bib52]).

MPO exhibits a crucial mechanistic junction between oxidation and inflammation ([@bib42]). Inducible nitric oxide synthase (iNos) is a calcium independent enzyme that is prominently induced in case of inflammation leading to generation of large amount of NO. Such events eventually result in massive tissue damage ([@bib44]; [@bib37]).

The current study revealed that diclofenac significantly elevated hepatic MPO content and iNOS protein expression, revealing that inflammation mediated diclofenac-induced hepatotoxicity. In line with this data, Nouri et al. showed that diclofenac elevated the expression of hepatic pro-inflammatory cytokines in rats ([@bib45]).

Moreover, the current study stated that diclofenac administration resulted in deterioration of the overall histopathological picture of the hepatic tissue of diclofenac-control group. The histopathological findings are in line with biochemical results.

In line with this data, El-Maddawy et al. stated that diclofenac administration resulted in hepatocellular necrosis, non-fatty degeneration and vacuolation ([@bib17]).

Royal jelly (RJ) is a natural honeybee product of young worker bees (*Apis mellifera Linne*) ([@bib4]). RJ has been shown to exhibit promising anti-oxidant ([@bib1]) and anti-inflammatory properties ([@bib30]).

In the current work, oral administration of RJ (150, 300 mg/kg) significantly reduced serum ALT and AST levels in diclofenac injected rats. These results reveal that RJ prevented hepatic enzyme leakage into the circulation, maintained hepatocyte membrane integrity and significantly provided hepatoprotective effects. Previous studies stated that RJ showed noticeable protective effect on hepatic tissue ([@bib28]; [@bib14]).

Moreover, oral administration of RJ protected against diclofenac-induced hepatic injury via significant elevation of COX-2 protein expression and hepatic PGE-2 content. Oka et al. also described the protective effect of RJ against experimentally-induced immunosupression by elevating PGE2 levels ([@bib46]).

According to the present study, RJ significantly reduced hepatic MPO content and iNOS protein expression revealing that it ameliorated diclofenac-induced hepatotoxicity via reducing hepatic tissue inflammation. This finding may be attributed to the anti-inflammatory activities of RJ which was described in previous studies ([@bib36]; [@bib30]). Additionally, it has been stated that tualang honey repressed UVB-induced iNOS protein expression, PGE2 production as well as COX-2 expression ([@bib3]).

Oral administration of RJ in the selected doses resulted in significant improvement of the hepatic tissue histopathological picture as compared to diclofenac-control group. This data is in line with the aforementioned biochemical and immunohistochemical findings.

Diclofenac injection resulted in significant impairment of renal function as measured by elevated serum urea and creatinine compared to normal rats. This can be attributed to absence of elimination of metabolized products from the body resulting in severe disruption of renal tubular function. This finding is in accordance with that of [@bib47]. Giridharan et al. also described significant deterioration in renal function as well as oxidative markers post diclofenac injection ([@bib23]).

Diclofenac injection significantly reduced renal COX-2 protein expression and thereby renal PGE-2 content. Therefore, it can be postulated that diclofenac-induced nephrotoxicity may have resulted from reduction of PGE-2 production due to COX-2 inhibition. Our results are in agreement with previous studies that stated that inhibition of prostaglandin production results in disruption of glomerular filtration rate as well as destruction of renal tubular function and renal metabolism ([@bib55]; [@bib50]). Moreover, diclofenac-control rats showed significant elevation in renal MPO content and iNOS protein expression showing that diclofenc-induced renal toxicity might be mediated through inflammation of renal tissue. Moreover, the histopathological picture of renal tissue of diclofenac-control rats showed severe deterioration as was manifested by massive areas of fibrosis, glomerular affection and ongoing cell apoptosis. These results are in agreement with those of El-Maddawy et al., who stated that diclofenac administration in rats resulted in severe renal tissue inflammation that was manifested by glomerulo-nephritis along with interstitial inflammation and renal tissue necrosis epithelium ([@bib17]). Additionally, Giridharan et al. demonstrated severe renal histopathological changes following diclofenac injection ([@bib23]).

In the current work, oral administration of RJ significantly reduced serum urea and creatinine as compared to diclofenac-control rats; thereby it improved and almost normalized renal function. Other studies demonstrated that RJ successfully restored renal function in cisplatin-induced nephrotoxicity ([@bib32]; [@bib26]).

Administration of RJ in the selected dose levels showed a significant increase in renal COX-2 protein expression and PGE-2 renal content leading eventually to significant protection against diclofenac toxicity. Moreover, RJ significantly reduced renal MPO content and iNOS protein expression. These data implicates that RJ reduced renal toxicity via inhibiting the inflammatory and pro-inflammatory responses. Prior studies described anti-inflammatory effects of RJ against ethylene glycol-induced renal inflammation in rats ([@bib5]).

In harmony with the aforementioned biochemical and immunohistochemical findings, diclofenac-induced renal histopathological damage was reversed by RJ treatment. This data is in line with previous studies that demonstrated the improvement of renal histological changes upon RJ treatment in diabetic rats ([@bib22]).

Diclofenac injected rats showed a significant increase in gastrointestinal ulcer count, indicating severe gastrointestinal damage as evidenced by histopathological changes. Diclofenac-control group showed abnormal histological structure of the gastric mucosa as was manifested by sloughing of superficial secreting cells along with inflammation and necrosis of the functioning cells of gastric glands along with inflammatory cellular infiltrate in the submucosa. Intestinal sections showed distorted histological structure of the villi with lining mucosal epithelium and serosa. This finding is similar to that demonstrated by Devi who described significant elevation in gastric ulcer lesion index in diclofenac-treated rats ([@bib16]). Giridharan et al. also described increasing gastrointestinal ulcer score in diclofenac-treated rats ([@bib23]). Khan et al. also described severe deterioration of the overall gastric histopathological pictures of diclofenac-injected rats as compared to normal rats ([@bib34]).

Furthermore, diclofenac-control rats exhibited significant reduction in COX-2 protein expression and PGE-2 content in the gastrointestinal tissue. Although COX-1 plays a vital role in maintaining the integrity of gastrointestinal mucosa, it has been demonstrated that COX-1 inhibition up-regulates COX-2 derived PGE-2 and thereby plays a compensatory role in maintaining the gastrointestinal functional properties. It has been reported that both COX-1 and COX-2 inhibition is required for gastrointestinal ulcerative properties of NSAIDS ([@bib53]). Therefore, diclofenac-induced gastrointestinal injury might be attributed to reduction of COX-1 and COX-2 derived PGE-2.

Additionally, diclofenac treated rats showed a significant increase in gastrointestinal MPO content and iNOS protein expression as compared to normal control rats. In line with previous studies, elevated MPO and iNOS activities result from COX-1 and COX-2 inhibition eventually leading to gastrointestinal damage ([@bib53]).

Administration of RJ in the selected dose levels significantly reduced gastrointestinal ulcer counts and attenuated histopathological changes. This data indicates its protective role against diclofenac-induced gastrointestinal damage in rats. These results are in line with those of Karaca et al. who demonstrated that RJ protected the mucosa of the colon against acetic acid-induced injury ([@bib29]). Moreover, RJ significantly elevated COX-2 protein expression and PGE-2 in the gastrointestinal tissue. RJ also significantly reduced MPO gastrointestinal content and iNOS protein expression, indicating it\'s anti-inflammatory effect. Kaynar et al. described the efficacy of RJ against methotrexate-induced small intestine damage in rats ([@bib33]). Prior studies also stated that RJ significantly improved colon histopathological pictures and protected colon mucosa against 2,4,6 trinitrobenzene sulfonic acid-induced colitis. These effects were mainly attributed to its mainly anti-inflammatory as well as antioxidant properties ([@bib31]).

6. Conclusion {#sec6}
=============

In the light of all findings, the current study suggests that royal jelly protects against diclofenac induced hepato-renal and gastrointestinal damage by elevating PGE-2 production and COX-2 protein expression as well as down-regulation of iNOS protein expression, eventually leading to reduction of the inflammatory response. The biochemical data is in parallel with amelioration of the hepatic, renal, gastric and intestinal tissues histopathological changes. Royal jelly could be a promising supplement to protect against diclofenac induced multiorgan damage. Further studies are needed to study the molecular mechanisms underlying this protective role.
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[^1]: Rats of the normal control group received I.P. injections of saline. Hepato-renal damage was induced in the remaining 3 groups by single intraperitoneal injection of diclofenac (50 mg/kg) for 7 days. Group 2 received only distilled water orally for 30 days and served as diclofenac-control group. Groups 3 & 4 received royal jelly (150 & 300 mg/kg/day, P.O.) respectively for 30 days. All animals were sacrificed 24 h after the last treatment after overnight fasting. Blood samples were collected and sera were separated.

[^2]: Data is presented as mean ± SEM (n = 10).

[^3]: ^a^Significantly different from Normal control groupat *p* \< 0.05 (*Tukey\'s* post hoc test).

[^4]: ^b^Significantly different from Diclofenac-control group at *p* \< 0.05 (*Tukey\'s* post hoc test).

[^5]: Rats of the normal control group received I.P. injections of saline. Gastrointestinal ulcerations were induced in the remaining 3 groups by single intraperitoneal injection of diclofenac (50 mg/kg) for 7 days. Group 2 received only distilled water orally for 30 days and served as diclofenac-control group. Groups 3 & 4 received royal jelly (150 & 300 mg/kg/day, P.O.) respectively for 30 days. All animals were sacrificed 24 h after the last treatment after overnight fasting. All animals were sacrificed 24 h after the last treatment after overnight fasting. The stomachs and intestines were removed and inspected for the ulcer count.

[^6]: Data is presented as mean ± SEM (n = 10).

[^7]: ^a^Significantly different from Normal control groupat *p* \< 0.05 (*Tukey\'s* post hoc test).

[^8]: ^b^Significantly different from Diclofenac-control group at *p* \< 0.05 (*Tukey\'s* post hoc test).

[^9]: Rats of the normal control group received I.P. injections of saline. Hepato-renal damage and gastrointestinal ulcerations were induced in the remaining 3 groups by single intraperitoneal injection of diclofenac (50 mg/kg) for 7 days. Group 2 received only distilled water orally for 30 days and served as diclofenac-control group. Groups 3 & 4 received royal jelly (150 & 300 mg/kg/day, P.O.) respectively for 30 days. All animals were sacrificed 24 h after the last treatment after overnight fasting. The liver, kidneys, stomachs and intestines were removed, homogenized and the homogenate was obtained.

[^10]: Data is presented as mean ± SEM (n = 10).

[^11]: ^a^Significantly different from Normal control groupat *p* \< 0.05 (*Tukey\'s* post hoc test).

[^12]: ^b^Significantly different from Diclofenac-control group at *p* \< 0.05 (*Tukey\'s* post hoc test).

[^13]: Rats of the normal control group received I.P. injections of saline. Hepato-renal damage and gastrointestinal ulcerations were induced in the remaining 3 groups by single intraperitoneal injection of diclofenac (50 mg/kg) for 7 days. Group 2 received only distilled water orally for 30 days and served as diclofenac-control group. Groups 3 & 4 received royal jelly (150 & 300 mg/kg/day, P.O.) respectively for 30 days. All animals were sacrificed 24 h after the last treatment after overnight fasting. The liver, kidneys, stomachs and intestines were removed, homogenized and the homogenate was obtained.

[^14]: Data is presented as mean ± SEM (n = 10).

[^15]: ^a^Significantly different from Normal control groupat *p* \< 0.05 (*Tukey\'s* post hoc test).

[^16]: ^b^Significantly different from Diclofenac-control group at *p* \< 0.05 (*Tukey\'s* post hoc test).
